{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:48:06Z","timestamp":1785883686969,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41440-026-02695-5","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T03:16:42Z","timestamp":1780543002000},"page":"2352-2365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on the management of blood pressure in Japanese patients with diabetes"],"prefix":"10.1038","volume":"49","author":[{"given":"Takaya","family":"Matsushita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masuo","family":"Saburi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiji","family":"Kawanami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Tsuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Wakui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keizo","family":"Kanasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimi","family":"Muta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"2695_CR1","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","volume":"18","author":"AB van der Aart-van der Beek","year":"2022","unstructured":"van der Aart-van der Beek AB, de Boer RA, Heerspink HJL. Kidney and heart failure outcomes associated with SGLT2 inhibitor use. Nat Rev Nephrol. 2022;18:294\u2013306.","journal-title":"Nat Rev Nephrol"},{"key":"2695_CR2","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"2695_CR3","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"2695_CR4","doi-asserted-by":"crossref","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","DOI":"10.1056\/NEJMoa2204233"},{"key":"2695_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann JFE, \u00d8rsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377:839\u201348.","journal-title":"N Engl J Med"},{"key":"2695_CR6","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med"},{"key":"2695_CR7","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896\u2013907.","journal-title":"N Engl J Med"},{"key":"2695_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet (Lond, Engl). 2019;394:131\u20138.","journal-title":"Lancet (Lond, Engl)"},{"key":"2695_CR9","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","volume":"30","author":"JFE Mann","year":"2024","unstructured":"Mann JFE, Rossing P, Bakris G, Belmar N, Bosch-Traberg H, Busch R, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med. 2024;30:2849\u201356.","journal-title":"Nat Med"},{"key":"2695_CR10","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1016\/S2213-8587(16)30267-4","volume":"4","author":"JP Fr\u00edas","year":"2016","unstructured":"Fr\u00edas JP, Guja C, Hardy E, Ahmed A, Dong F, \u00d6hman P, et al. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diab Endocrinol. 2016;4:1004\u201316.","journal-title":"Lancet Diab Endocrinol"},{"key":"2695_CR11","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diab Endocrinol. 2019;7:356\u201367.","journal-title":"Lancet Diab Endocrinol"},{"key":"2695_CR12","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4330\/wjc.v14.i6.329","volume":"14","author":"AK Singh","year":"2022","unstructured":"Singh AK, Singh R. Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. World J Cardiol. 2022;14:329\u201342.","journal-title":"World J Cardiol"},{"key":"2695_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0942-x","volume":"18","author":"LE Clegg","year":"2019","unstructured":"Clegg LE, Penland RC, Bachina S, Boulton DW, Thuresson M, Heerspink HJL, et al. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetol. 2019;18:138.","journal-title":"Cardiovascular Diabetol"},{"key":"2695_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/dom.14179","volume":"23","author":"A Cahn","year":"2021","unstructured":"Cahn A, Wiviott SD, Mosenzon O, Murphy SA, Goodrich EL, Yanuv I, et al. Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. Diab, Obes Metab. 2021;23:29\u201338.","journal-title":"Diab, Obes Metab"},{"key":"2695_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2337\/dc21-1113","volume":"45","author":"AK Wright","year":"2022","unstructured":"Wright AK, Carr MJ, Kontopantelis E, Leelarathna L, Thabit H, Emsley R, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diab care. 2022;45:909\u201318.","journal-title":"Diab care"},{"key":"2695_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1161\/CIRCULATIONAHA.121.057934","volume":"145","author":"CSP Lam","year":"2022","unstructured":"Lam CSP, Ramasundarahettige C, Branch KRH, Sattar N, Rosenstock J, Pratley R, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022;145:565\u201374.","journal-title":"Circulation"},{"key":"2695_CR17","doi-asserted-by":"crossref","unstructured":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102:S1\u2013s127.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"2695_CR18","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","volume":"45","author":"MJ Davies","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab care. 2022;45:2753\u201386.","journal-title":"Diab care"},{"key":"2695_CR19","doi-asserted-by":"crossref","unstructured":"Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, Tsuriya D, et al. Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication. Diabetes Vascular Dis Res. 2023;20:14791641231222837.","DOI":"10.1177\/14791641231222837"},{"key":"2695_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1358573","volume":"15","author":"Y Muta","year":"2024","unstructured":"Muta Y, Kobayashi K, Toyoda M, Tone A, Suzuki D, Tsuriya D, et al. Influence of the combination of SGLT2 inhibitors and GLP-1 receptor agonists on eGFR decline in type 2 diabetes: post-hoc analysis of RECAP study. Front Pharm. 2024;15:1358573.","journal-title":"Front Pharm"},{"key":"2695_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"2695_CR22","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7326\/M20-0529","volume":"173","author":"K Sumida","year":"2020","unstructured":"Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, et al. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis : an individual participant-based meta-analysis. Ann Intern Med. 2020;173:426\u201335.","journal-title":"Ann Intern Med"},{"key":"2695_CR23","doi-asserted-by":"crossref","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","DOI":"10.1038\/s41440-019-0284-9"},{"key":"2695_CR24","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/BF02924688","volume":"31","author":"H Toutenburg","year":"1990","unstructured":"Toutenburg H, Rubin DB. Multiple imputation for nonresponse in surveys. Stat Pap. 1990;31:180.","journal-title":"Stat Pap"},{"key":"2695_CR25","doi-asserted-by":"crossref","unstructured":"Enders CK, Little TD Applied missing data analysis. https:\/\/ci.nii.ac.jp\/ncid\/BB02100335). Guilford Press 2010.","DOI":"10.1002\/9780470479216.corpsy0552"},{"key":"2695_CR26","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/ki.2012.74","volume":"82","author":"HJL Heerspink","year":"2012","unstructured":"Heerspink HJL, Holtkamp FA, Parving H-H, Navis GJ, Lewis JB, Ritz E, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 2012;82:330\u20137.","journal-title":"Kidney Int"},{"key":"2695_CR27","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1111\/dom.15652","volume":"26","author":"S Tsukamoto","year":"2024","unstructured":"Tsukamoto S, Kobayashi K, Toyoda M, Tone A, Kawanami D, Suzuki D, et al. Effect of preceding drug therapy on the renal and cardiovascular outcomes of combined sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes and chronic kidney disease. Diab, Obes Metab. 2024;26:3248\u201360.","journal-title":"Diab, Obes Metab"},{"key":"2695_CR28","volume":"17","author":"D Tantawy","year":"2025","unstructured":"Tantawy D, Musa Rabih MR, Ibrahim Mohamed RS, Abdelrahman Ali MO, Mohammed Saad Aldeen RSA, Ahmed Abdelkarim AO, et al. Cardiometabolic benefits and risks of sodium-glucose co-transporter-2 (SGLT-2) inhibitor and glucagon-like peptide-1 (GLP-1) receptor agonist combination therapy in type 2 diabetes: a systematic review. Cureus. 2025;17:e96218.","journal-title":"Cureus"},{"key":"2695_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-025-01342-7","volume":"27","author":"AK Siddiqi","year":"2025","unstructured":"Siddiqi AK, Khan MS, Kulkarni A, Hall ME, B\u00f6hm M, D\u00edez J, et al. Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists. Curr Hypertens Rep. 2025;27:28.","journal-title":"Curr Hypertens Rep"},{"key":"2695_CR30","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"2695_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s40885-024-00279-4","volume":"30","author":"HY Lee","year":"2024","unstructured":"Lee HY, Ko SH, Park S, Kim K, Kim SY, Cho IJ, et al. The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension. Clin Hypertens. 2024;30:24.","journal-title":"Clin Hypertens"},{"key":"2695_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40360-017-0125-x","volume":"18","author":"S Kawasoe","year":"2017","unstructured":"Kawasoe S, Maruguchi Y, Kajiya S, Uenomachi H, Miyata M, Kawasoe M, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18:23.","journal-title":"BMC Pharmacol Toxicol"},{"key":"2695_CR33","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2147\/VHRM.S111991","volume":"12","author":"JW Reed","year":"2016","unstructured":"Reed JW. Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag. 2016;12:393\u2013405.","journal-title":"Vasc Health Risk Manag"},{"key":"2695_CR34","doi-asserted-by":"publisher","first-page":"F1295","DOI":"10.1152\/ajprenal.00202.2018","volume":"315","author":"KM Hallow","year":"2018","unstructured":"Hallow KM, Greasley PJ, Helmlinger G, Chu L, Heerspink HJ, Boulton DW. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. Am J Physiol Ren Physiol. 2018;315:F1295\u2013F306.","journal-title":"Am J Physiol Ren Physiol"},{"key":"2695_CR35","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, Avgerinos I, Mantsiou C, Tousinas G, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis. Diab, Obes Metab. 2021;23:2116\u201324.","journal-title":"Diab, Obes Metab"},{"key":"2695_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/dom.15312","volume":"26","author":"S Tsukamoto","year":"2024","unstructured":"Tsukamoto S, Tanaka S, Yamada T, Uneda K, Azushima K, Kinguchi S, et al. Effect of tirzepatide on glycaemic control and weight loss compared with other glucagon-like peptide-1 receptor agonists in Japanese patients with type 2 diabetes mellitus. Diab, Obes Metab. 2024;26:262\u201374.","journal-title":"Diab, Obes Metab"},{"key":"2695_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.109231","volume":"185","author":"K Kobayashi","year":"2022","unstructured":"Kobayashi K, Toyoda M, Hatori N, Sakai H, Furuki T, Chin K, et al. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diab Res Clin Pract. 2022;185:109231.","journal-title":"Diab Res Clin Pract"},{"key":"2695_CR38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","volume":"48","author":"HJ Wong","year":"2025","unstructured":"Wong HJ, Sim B, Teo YH, Teo YN, Chan MY, Yeo LLL, et al. Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials. Diab Care. 2025;48:292\u2013300.","journal-title":"Diab Care"},{"key":"2695_CR39","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H, Le S, Liu Y, Ao X, et al. The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr. 2023;118:614\u201326.","journal-title":"Am J Clin Nutr"},{"key":"2695_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100:215\u201324.","journal-title":"Kidney Int"},{"key":"2695_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(23)00322-4","volume":"12","author":"P Judge","year":"2024","unstructured":"Judge P, Staplin N, Mayne K, Wanner C, Green J, Hauske S, et al. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diab Endocrinol. 2024;12:51\u201360.","journal-title":"Lancet Diab Endocrinol"},{"key":"2695_CR42","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1038\/s41440-023-01366-z","volume":"46","author":"K Kobayashi","year":"2023","unstructured":"Kobayashi K, Chin K, Hatori N, Furuki T, Sakai H, Miyakawa M, et al. Cross-sectional survey of hypertension management in clinical practice in Japan: The Kanagawa Hypertension Study 2021 conducted in collaboration with Japan Medical Association Database of Clinical Medicine. Hypertens Res. 2023;46:2447\u201359.","journal-title":"Hypertens Res"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02695-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02695-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:07:00Z","timestamp":1785881220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-026-02695-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2695"],"URL":"https:\/\/doi.org\/10.1038\/s41440-026-02695-5","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"13 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KK has received lecture fees from Otsuka Pharmaceutical and Novartis. Hiromichi Wakui has received research supports from AstraZeneca, Otsuka Pharmaceutical, and Kaneka Corporation, and honoraria from AstraZeneca, Otsuka Pharmaceutical, Kaneka Corporation, Kyowa Kirin, Sanwa Kagaku, Chugai Pharma, Kowa, Otsuka Pharmaceutical, Novartes, Mitsubishi-Tanabe Pharma, Bayer, and Daiichi-Sankyo Pharma. MT received lecture fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sumitomo, and Mitsubishi Tanabe and received subsidies from Super Light Water, TAKAGI, Roche DC, and LifeScan. Kouichi Tamura has received honoraria\/lecture fee from AstraZeneca, Novartes, Bayer, Otsuka Pharmaceutical, Boehringer Ingelheim, Fuji Pharma, Kyowa Kirin, Ono Pharmaceutical, Sanwa Kagaku, Mochida Pharmaceutical, Kowa, Eli Lilly, Novo Nordisk, commissioned clinical trials, contract research and joint research funding: AstraZeneca, Bayer, Novartis, Chinook, Otsuka Medical Devices, Novo Nordisk, Terumo, Variatris, and Kowa, and, Scholarship donations: Otsuka Pharmaceutical, Bayer, Mochida Pharmaceutical, and Boehringer Ingelheim. Daisuke Tsuriya received lecture fees from Eli Lilly, Novo Nordisk Pharma, and Tanabe Pharma Corporation. Daiji Kawanami received consulting\/lecture fees from Bayer Yakuhin Ltd., Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Eli Lilly Japan KK, Daiichi Sankyo Co., Ltd., and Sumitomo Pharma Co., Ltd., and grants from Nipro Corporation, Sumitomo Pharma Co., Ltd., and Tanabe Pharma Corporation. Keizo Kanasaki were supported by grants from the Japan Society for the Promotion of Science to Keizo Kanasaki (25K11544). KK collaborated with Boehringer Ingelheim, Kowa, Bayer, and Mitsubishi. KK received lecture honoraria from Sumitomo Pharma, Astra Zeneca, Otsuka, Taisho Pharma, Tanabe-Mitsubishi, Eli Lilly, Boehringer-Ingelheim, Novo Nordisk, Bayer, Novartis, and Kowa.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}